We are thrilled to announce that Biocytogen will be an exhibitor at RESI San Diego. Icy Niu, Executive Director and Global BD & Marketing Head, will host a workshop between 10:00 - 10:50 a.m. on the newly launched RenSuper Workstation: An AI-Driven Antibody Discovery Platform From Target to Antibody Leads in Click. Don’t miss this opportunity to connect with our team and learn how Biocytogen can support and accelerate your drug discovery journey.
What is RESI?
Redefining Every Stage Investments (RESI) is a collection of conferences that provide premier platforms to bridge science and business. They drive the advancement of innovation across drugs, devices, diagnostics and digital health by connecting early-stage biotech startups with investors and strategic channel partners.
Event Overview
Date: June 22nd, 2026
Venue: JULEP Venue, 1735 Hancock St, San Diego, CA 92101
Event Schedule
For more information, please refer to the event webpage.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to advancing healthcare innovation together, let’s connect in San Diego, CA!
